Latest Insider Transactions at Replimune Group, Inc. (REPL)
This section provides a real-time view of insider transactions for Replimune Group, Inc. (REPL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Replimune Group, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Replimune Group, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.72%
|
$120,000
$12.42 P/Share
|
|
Nov 18
2024
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,207
-5.64%
|
$52,070
$10.78 P/Share
|
|
Nov 18
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,246
-6.19%
|
$72,460
$10.78 P/Share
|
|
Aug 30
2024
|
Philip Astley Sparke Executive Chairman |
SELL
Bona fide gift
|
Direct |
50,000
-3.36%
|
-
|
|
Aug 16
2024
|
Emily Luisa Hill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,938
-8.13%
|
$89,380
$10.18 P/Share
|
|
Jun 07
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,881
-11.94%
|
$111,167
$7.5 P/Share
|
|
May 16
2024
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,615
-2.22%
|
$105,690
$6.47 P/Share
|
|
May 16
2024
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,298
-5.67%
|
$13,788
$6.47 P/Share
|
|
May 16
2024
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,218
-2.35%
|
$13,308
$6.47 P/Share
|
|
May 16
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,367
-4.57%
|
$38,202
$6.47 P/Share
|
|
May 16
2024
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,194
-8.7%
|
$121,164
$6.47 P/Share
|
|
May 16
2024
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
11,464
-0.63%
|
$68,784
$6.47 P/Share
|
|
May 16
2024
|
Philip Astley Sparke Executive Chairman |
SELL
Open market or private sale
|
Direct |
37,928
-2.49%
|
$227,568
$6.47 P/Share
|
|
Apr 01
2024
|
Andrew Schwendenman Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,775
+30.48%
|
-
|
|
Apr 01
2024
|
Christopher Sarchi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,225
+19.05%
|
-
|
|
Apr 01
2024
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,665
+19.51%
|
-
|
|
Apr 01
2024
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,665
+16.06%
|
-
|
|
Apr 01
2024
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,335
+26.41%
|
-
|
|
Nov 16
2023
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,255
-6.78%
|
$52,550
$10.92 P/Share
|
|
Nov 16
2023
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,313
-6.09%
|
$73,130
$10.92 P/Share
|
|
Sep 18
2023
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,330
+50.0%
|
-
|
|
Sep 12
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
300
-0.11%
|
$6,000
$20.0 P/Share
|
|
Sep 12
2023
|
Pamela Esposito Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.11%
|
$900
$3.3 P/Share
|
|
Sep 11
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,358
-1.99%
|
$107,160
$20.01 P/Share
|
|
Sep 11
2023
|
Pamela Esposito Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,358
+1.95%
|
$16,074
$3.3 P/Share
|
|
Aug 22
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
18,600
-6.59%
|
$372,000
$20.01 P/Share
|
|
Aug 22
2023
|
Pamela Esposito Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,600
+3.21%
|
$167,400
$9.4 P/Share
|
|
Aug 11
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,400
-0.53%
|
$28,000
$20.0 P/Share
|
|
Aug 11
2023
|
Pamela Esposito Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+0.53%
|
$4,200
$3.3 P/Share
|
|
Jul 10
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
20,000
-3.55%
|
$420,000
$21.38 P/Share
|
|
Jul 10
2023
|
Pamela Esposito Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.42%
|
$180,000
$9.4 P/Share
|
|
Jun 13
2023
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,698
-1.85%
|
$131,054
$23.78 P/Share
|
|
Jun 13
2023
|
Tanya Lewis Chief Dev. Op. Officer |
SELL
Open market or private sale
|
Direct |
12,860
-4.36%
|
$295,780
$23.78 P/Share
|
|
May 16
2023
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
7,861
-0.43%
|
$141,498
$18.05 P/Share
|
|
May 16
2023
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,575
-9.15%
|
$280,350
$18.05 P/Share
|
|
May 16
2023
|
Philip Astley Sparke Executive Chairman |
SELL
Open market or private sale
|
Direct |
17,902
-1.16%
|
$322,236
$18.05 P/Share
|
|
May 16
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,966
-2.21%
|
$107,388
$18.05 P/Share
|
|
May 16
2023
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
771
-0.64%
|
$13,878
$18.05 P/Share
|
|
May 16
2023
|
Jean M. Franchi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,351
-8.1%
|
$204,318
$18.05 P/Share
|
|
May 16
2023
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,775
-1.34%
|
$193,950
$18.05 P/Share
|
|
May 16
2023
|
Tanya Lewis Chief Dev. Op. Officer |
SELL
Open market or private sale
|
Direct |
12,207
-7.61%
|
$219,726
$18.05 P/Share
|
|
Apr 01
2023
|
Philip Astley Sparke Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
142,100
+8.43%
|
-
|
|
Apr 01
2023
|
Robert Coffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.39%
|
-
|
|
Apr 01
2023
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.03%
|
-
|
|
Apr 01
2023
|
Tanya Lewis Chief Dev. Op. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.96%
|
-
|
|
Apr 01
2023
|
Colin Love Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+4.73%
|
-
|
|
Apr 01
2023
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+24.31%
|
-
|
|
Apr 01
2023
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+29.27%
|
-
|
|
Apr 01
2023
|
Pamela Esposito Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+12.93%
|
-
|
|
Dec 09
2022
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
15,000
-6.14%
|
$375,000
$25.03 P/Share
|